A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
Price : $35 *
At a glance
- Drugs DCVAC OvCa (Primary) ; Doxorubicin; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 01 Dec 2016 This trial was completed in Poland (end date: 2016-08-02), according to European Clinical Trials Database.
- 29 Nov 2016 Status changed from active, no longer recruiting to discontinued.
- 21 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.